Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis — are we there yet?

Lucchinetti C. , Bruck W. , Parisi J. , Scheithauer B. , Rodriguez M. , Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707—17.

Smith PA , Heijmans N. , Ouwerling B. et al. Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice. Eur J Immunol 2005; 35(4): 1311—9.

Morris-Downes MM , Smith PA , Rundle JL et al. Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice . J Neuroimmunol 2002; 125(1—2): 114—24.

Burrer R. , Buchmeier MJ , Wolfe T. et al. Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. Am J Pathol 2007; 170(2): 557—66.

Wallberg M. , Bergquist J. , Achour A. , Breij E. , Harris RA Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to increased immunogenicity and encephalitogenicity. Eur J Immunol 2007; 37(7): 1986—95.

Xiao BG , Linington C. , Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991; 31(2): 91—6.

Berger T. , Rubner P. , Schautzer F. et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349(2): 139—45.

Tomassini V. , De Giglio L. , Reindl M. et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Mult Scler 2007;

Lim ET , Berger T. , Reindl M. et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11(4): 492—4.

Rauer S. , Euler B. , Reindl M. , Berger T. Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J Neurol Neurosurg Psychiatry 2006; 77(6): 739—42.

Pelayo R. , Tintore M. , Montalban X. et al. Antimyelin antibodies with no progression to multiple sclerosis . N Engl J Med 2007; 356(4): 426—8.

Pittock SJ , Reindl M. , Achenbach S. et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations . Mult Scler 2007; 13(1): 7—16.

Kuhle J. , Lindberg RL , Regeniter A. et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007; 254(2): 160—8.

Kuhle J. , Pohl C. , Mehling M. et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007; 356(4): 371—8.

Lampasona V. , Franciotta D. , Furlan R. et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004; 62(11): 2092—4.

Lalive PH , Menge T. , Delarasse C. et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103(7): 2280—5.

Zhou D. , Srivastava R. , Nessler S. et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103(50): 19057—62.

O'Connor KC , McLaughlin KA , De Jager PL et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007; 13(2): 211—7.

Lucchinetti CF , Bruck W. , Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56(2): 308.

Marta CB , Oliver AR , Sweet RA , Pfeiffer SE , Ruddle NH Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci U S A 2005; 102(39): 13992—7.